Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
These drugs are bad for them? I had only heard of other benefits from them. No doubt a PR campaign, along with aggressively shutting down any negative stories/studies with the usual tactics, pioneered by big tobacco and now adopted by all the polluters and poisoners.